Story perspectives

Personalized mRNA vaccine cuts melanoma recurrence risk 42%

By Drooid · Oct 23, 2026, 6:22 AM UTC · How we work

Summary

Story summary

Professor Georgina Long’s team showed a personalized mRNA vaccine reduced melanoma recurrence or death risk by 42%.
The Phase 3 trial enrolled 1,137 patients, with two-thirds receiving the vaccine.
At two years, 82% of vaccine patients were melanoma-free versus 70% with immunotherapy alone.
Researchers sequenced each tumour to target up to 34 unique neoantigens.
Associate Professor Seth Cheetham called the combo an ‘incredible breakthrough’ for cancer care.

1 of 1

Story summary

Professor Georgina Long’s team showed a personalized mRNA vaccine reduced melanoma recurrence or death risk by 42%.
The Phase 3 trial enrolled 1,137 patients, with two-thirds receiving the vaccine.
At two years, 82% of vaccine patients were melanoma-free versus 70% with immunotherapy alone.
Researchers sequenced each tumour to target up to 34 unique neoantigens.
Associate Professor Seth Cheetham called the combo an ‘incredible breakthrough’ for cancer care.